Long term safety data for the first generation of CXCR4 antagonists used for patients with acute myeloid leukemia, where a high CXCR4 expression is linked to poor progression [11], demonstrates that CXCR4 inhibition is a well-tolerated approach. The gene discussed is CXCR4; the disease is acute myeloid leukemia.